CA2028849A1 - Anticorps monoclonaux, methode de dosage, trousse de reactifs, methode de recherche et medicaments missiles y faisant appel - Google Patents

Anticorps monoclonaux, methode de dosage, trousse de reactifs, methode de recherche et medicaments missiles y faisant appel

Info

Publication number: CA2028849A1
Authority: CA; Canada
Prior art keywords: lower alkyl; monoclonal antibody; cytidine; monoclonal antibodies; recognize
Prior art date: 1990-03-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2028849

Other languages

English (en)

Inventor

Michinao Mizugaki

Kunihiko Itoh

Nakao Ishida

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SENDAI INSTITUTE OF MICROBIOLOGY (THE)

Original Assignee

SENDAI INSTITUTE OF MICROBIOLOGY (THE)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-08

Filing date

1990-03-08

Publication date

1991-09-09

1990-03-08 Application filed by SENDAI INSTITUTE OF MICROBIOLOGY (THE) filed Critical SENDAI INSTITUTE OF MICROBIOLOGY (THE)

1990-03-08 Priority to CA 2028849 priority Critical patent/CA2028849A1/fr

1991-09-09 Publication of CA2028849A1 publication Critical patent/CA2028849A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 47
238000003556 assay Methods 0.000 title claims abstract description 19
229940079593 drug Drugs 0.000 title claims abstract description 18
239000003814 drug Substances 0.000 title claims abstract description 18
239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 14
210000004408 hybridoma Anatomy 0.000 claims abstract description 23
238000003745 diagnosis Methods 0.000 claims abstract description 7
230000002055 immunohistochemical effect Effects 0.000 claims abstract description 6
ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 claims description 38
ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical group O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 claims description 38
206010028980 Neoplasm Diseases 0.000 claims description 25
210000001519 tissue Anatomy 0.000 claims description 23
125000003835 nucleoside group Chemical group 0.000 claims description 18
210000004027 cell Anatomy 0.000 claims description 17
239000000126 substance Substances 0.000 claims description 16
241001465754 Metazoa Species 0.000 claims description 12
239000002777 nucleoside Substances 0.000 claims description 12
102100034613 Annexin A2 Human genes 0.000 claims description 10
108090000668 Annexin A2 Proteins 0.000 claims description 10
206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
201000000050 myeloid neoplasm Diseases 0.000 claims description 9
150000003833 nucleoside derivatives Chemical class 0.000 claims description 9
210000004989 spleen cell Anatomy 0.000 claims description 9
102000039446 nucleic acids Human genes 0.000 claims description 7
108020004707 nucleic acids Proteins 0.000 claims description 7
150000007523 nucleic acids Chemical class 0.000 claims description 7
230000002163 immunogen Effects 0.000 claims description 6
230000004060 metabolic process Effects 0.000 claims description 6
230000002159 abnormal effect Effects 0.000 claims description 5
230000001093 anti-cancer Effects 0.000 claims description 5
230000003327 cancerostatic effect Effects 0.000 claims description 5
238000003384 imaging method Methods 0.000 claims description 5
108090000669 Annexin A4 Proteins 0.000 claims description 4
102100034612 Annexin A4 Human genes 0.000 claims description 4
230000004927 fusion Effects 0.000 claims description 4
230000001900 immune effect Effects 0.000 claims description 4
230000003053 immunization Effects 0.000 claims description 4
230000036046 immunoreaction Effects 0.000 claims description 4
239000000941 radioactive substance Substances 0.000 claims description 3
230000005298 paramagnetic effect Effects 0.000 claims description 2
GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical group C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 claims 2
229930185560 Pseudouridine Natural products 0.000 claims 2
PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims 2
WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims 2
PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims 2
239000012472 biological sample Substances 0.000 claims 1
210000001124 body fluid Anatomy 0.000 abstract description 8
239000010839 body fluid Substances 0.000 abstract description 8
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 description 11
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
239000002953 phosphate buffered saline Substances 0.000 description 10
108091003079 Bovine Serum Albumin Proteins 0.000 description 9
229940098773 bovine serum albumin Drugs 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
239000000243 solution Substances 0.000 description 9
210000002700 urine Anatomy 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
102100025275 Monocarboxylate transporter 3 Human genes 0.000 description 7
108091006607 SLC16A8 Proteins 0.000 description 7
238000002372 labelling Methods 0.000 description 7
239000002609 medium Substances 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
238000010186 staining Methods 0.000 description 6
239000000758 substrate Substances 0.000 description 6
238000002835 absorbance Methods 0.000 description 5
238000001514 detection method Methods 0.000 description 5
230000002349 favourable effect Effects 0.000 description 5
230000000750 progressive effect Effects 0.000 description 5
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 4
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
239000011521 glass Substances 0.000 description 4
238000003018 immunoassay Methods 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
238000012360 testing method Methods 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
208000000461 Esophageal Neoplasms Diseases 0.000 description 3
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
102100025274 Monocarboxylate transporter 6 Human genes 0.000 description 3
108091006602 SLC16A5 Proteins 0.000 description 3
108091006603 SLC16A6 Proteins 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
239000000427 antigen Substances 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000007853 buffer solution Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
201000004101 esophageal cancer Diseases 0.000 description 3
108060003552 hemocyanin Proteins 0.000 description 3
238000002649 immunization Methods 0.000 description 3
230000009257 reactivity Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
239000000439 tumor marker Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
YUDSCJBUWTYENI-VPCXQMTMSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]pyrimidin-2-one Chemical compound C1=CC(N)=NC(=O)N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O YUDSCJBUWTYENI-VPCXQMTMSA-N 0.000 description 2
240000003291 Armoracia rusticana Species 0.000 description 2
238000011725 BALB/c mouse Methods 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
102100027871 Monocarboxylate transporter 8 Human genes 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010030155 Oesophageal carcinoma Diseases 0.000 description 2
108091006599 SLC16A2 Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000011088 calibration curve Methods 0.000 description 2
230000001268 conjugating effect Effects 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
238000012744 immunostaining Methods 0.000 description 2
108010014723 immunosuppressive acidic protein Proteins 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
238000002955 isolation Methods 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
230000004807 localization Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
241000894007 species Species 0.000 description 2
230000004960 subcellular localization Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
LSNXXQLUOJPKHX-UHFFFAOYSA-N 4-amino-1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-methylpyrimidin-2-one Chemical compound CC1=CC(N)=NC(=O)N1C1C(O)C(O)C(CO)O1 LSNXXQLUOJPKHX-UHFFFAOYSA-N 0.000 description 1
QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
102000012406 Carcinoembryonic Antigen Human genes 0.000 description 1
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
102100021906 Cyclin-O Human genes 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
102000004641 Fetal Proteins Human genes 0.000 description 1
108010003471 Fetal Proteins Proteins 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
229910052688 Gadolinium Inorganic materials 0.000 description 1
101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
241000711408 Murine respirovirus Species 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108010088160 Staphylococcal Protein A Proteins 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
239000011324 bead Substances 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
210000000969 egg white Anatomy 0.000 description 1
235000014103 egg white Nutrition 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Substances OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
229940093476 ethylene glycol Drugs 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
KPMKNHGAPDCYLP-UHFFFAOYSA-N nimustine hydrochloride Chemical compound Cl.CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 KPMKNHGAPDCYLP-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000008055 phosphate buffer solution Substances 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
-1 polyethylene Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CA 2028849 1990-03-08 1990-03-08 Anticorps monoclonaux, methode de dosage, trousse de reactifs, methode de recherche et medicaments missiles y faisant appel Abandoned CA2028849A1 (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2028849 CA2028849A1 (fr)	1990-03-08	1990-03-08	Anticorps monoclonaux, methode de dosage, trousse de reactifs, methode de recherche et medicaments missiles y faisant appel

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA 2028849 CA2028849A1 (fr)	1990-03-08	1990-03-08	Anticorps monoclonaux, methode de dosage, trousse de reactifs, methode de recherche et medicaments missiles y faisant appel

Publications (1)

Publication Number	Publication Date
CA2028849A1 true CA2028849A1 (fr)	1991-09-09

Family

ID=4146285

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2028849 Abandoned CA2028849A1 (fr)	1990-03-08	1990-03-08	Anticorps monoclonaux, methode de dosage, trousse de reactifs, methode de recherche et medicaments missiles y faisant appel

Country Status (1)

Country	Link
CA (1)	CA2028849A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015196118A1 (fr) *	2014-06-19	2015-12-23	Moderna Therapeutics, Inc.	Molécules d'acide nucléique différentes et utilisations
US10077439B2 (en)	2013-03-15	2018-09-18	Modernatx, Inc.	Removal of DNA fragments in mRNA production process
US10138507B2 (en)	2013-03-15	2018-11-27	Modernatx, Inc.	Manufacturing methods for production of RNA transcripts
US10286086B2 (en)	2014-06-19	2019-05-14	Modernatx, Inc.	Alternative nucleic acid molecules and uses thereof
US10385106B2 (en)	2012-04-02	2019-08-20	Modernatx, Inc.	Modified polynucleotides for the production of secreted proteins
US10385088B2 (en)	2013-10-02	2019-08-20	Modernatx, Inc.	Polynucleotide molecules and uses thereof
US10407683B2 (en)	2014-07-16	2019-09-10	Modernatx, Inc.	Circular polynucleotides
US10590161B2 (en)	2013-03-15	2020-03-17	Modernatx, Inc.	Ion exchange purification of mRNA
US10772975B2 (en)	2012-04-02	2020-09-15	Modernatx, Inc.	Modified Polynucleotides for the production of biologics and proteins associated with human disease
US10898574B2 (en)	2011-03-31	2021-01-26	Modernatx, Inc.	Delivery and formulation of engineered nucleic acids
US11027025B2 (en)	2013-07-11	2021-06-08	Modernatx, Inc.	Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
US11377470B2 (en)	2013-03-15	2022-07-05	Modernatx, Inc.	Ribonucleic acid purification
US11434486B2 (en)	2015-09-17	2022-09-06	Modernatx, Inc.	Polynucleotides containing a morpholino linker
US12109274B2 (en)	2015-09-17	2024-10-08	Modernatx, Inc.	Polynucleotides containing a stabilizing tail region
US12385034B2 (en)	2016-06-24	2025-08-12	Modernatx, Inc.	Methods and apparatus for filtration

1990
- 1990-03-08 CA CA 2028849 patent/CA2028849A1/fr not_active Abandoned

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10898574B2 (en)	2011-03-31	2021-01-26	Modernatx, Inc.	Delivery and formulation of engineered nucleic acids
US12409226B2 (en)	2011-03-31	2025-09-09	Modernatx, Inc.	Delivery and formulation of engineered nucleic acids
US11911474B2 (en)	2011-03-31	2024-02-27	Modernatx, Inc.	Delivery and formulation of engineered nucleic acids
US12419957B2 (en)	2011-03-31	2025-09-23	Modernatx, Inc.	Delivery and formulation of engineered nucleic acids
US12364763B2 (en)	2011-03-31	2025-07-22	Modernatx, Inc.	Delivery and formulation of engineered nucleic acids
US10385106B2 (en)	2012-04-02	2019-08-20	Modernatx, Inc.	Modified polynucleotides for the production of secreted proteins
US10577403B2 (en)	2012-04-02	2020-03-03	Modernatx, Inc.	Modified polynucleotides for the production of secreted proteins
US10703789B2 (en)	2012-04-02	2020-07-07	Modernatx, Inc.	Modified polynucleotides for the production of secreted proteins
US10772975B2 (en)	2012-04-02	2020-09-15	Modernatx, Inc.	Modified Polynucleotides for the production of biologics and proteins associated with human disease
US11845772B2 (en)	2013-03-15	2023-12-19	Modernatx, Inc.	Ribonucleic acid purification
US10590161B2 (en)	2013-03-15	2020-03-17	Modernatx, Inc.	Ion exchange purification of mRNA
US10858647B2 (en)	2013-03-15	2020-12-08	Modernatx, Inc.	Removal of DNA fragments in mRNA production process
US10077439B2 (en)	2013-03-15	2018-09-18	Modernatx, Inc.	Removal of DNA fragments in mRNA production process
US11377470B2 (en)	2013-03-15	2022-07-05	Modernatx, Inc.	Ribonucleic acid purification
US10138507B2 (en)	2013-03-15	2018-11-27	Modernatx, Inc.	Manufacturing methods for production of RNA transcripts
US11027025B2 (en)	2013-07-11	2021-06-08	Modernatx, Inc.	Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
US10385088B2 (en)	2013-10-02	2019-08-20	Modernatx, Inc.	Polynucleotide molecules and uses thereof
US10286086B2 (en)	2014-06-19	2019-05-14	Modernatx, Inc.	Alternative nucleic acid molecules and uses thereof
WO2015196118A1 (fr) *	2014-06-19	2015-12-23	Moderna Therapeutics, Inc.	Molécules d'acide nucléique différentes et utilisations
US10407683B2 (en)	2014-07-16	2019-09-10	Modernatx, Inc.	Circular polynucleotides
US12109274B2 (en)	2015-09-17	2024-10-08	Modernatx, Inc.	Polynucleotides containing a stabilizing tail region
US12071620B2 (en)	2015-09-17	2024-08-27	Modernatx, Inc.	Polynucleotides containing a morpholino linker
US11434486B2 (en)	2015-09-17	2022-09-06	Modernatx, Inc.	Polynucleotides containing a morpholino linker
US12385034B2 (en)	2016-06-24	2025-08-12	Modernatx, Inc.	Methods and apparatus for filtration

Publication	Publication Date	Title
US6326159B1 (en)	2001-12-04	Receptors for immune complexes
US9309312B2 (en)	2016-04-12	Immunoassay method for human CXCL1 protein
US20070166776A1 (en)	2007-07-19	Immunoassay and kit for an early and simultaneous detection of biochemical markers in a patient's sample
CA2028849A1 (fr)	1991-09-09	Anticorps monoclonaux, methode de dosage, trousse de reactifs, methode de recherche et medicaments missiles y faisant appel
CA2008360A1 (fr)	1990-07-23	Essai immunologique pour le diagnostic de l'infarctus du myocarde
JP2016500659A (ja)	2016-01-14	抗ウロプラキンｉｉ抗体システムおよび方法
JP2000502888A (ja)	2000-03-14	トピラメートのイムノアッセイ、並びに類似体及び抗体
US6946547B2 (en)	2005-09-20	Ecstasy-class analogs and use of same in detection of ecstasy-class compounds
JPS60501075A (ja)	1985-07-11	ヒトガン疾患診断法及びテストキツト
CA1251729A (fr)	1989-03-28	Methode de diagnostic in vitro faisant appel a des anticorps monoclonaux contre des proteines du tissu conjonctif
JPS60500427A (ja)	1985-03-28	特異性ｃｅａファミリ−抗原、それに対し特異性の抗体およびそれらの使用方法
JP4183777B2 (ja)	2008-11-19	インドキシル硫酸誘導体、抗原、抗体及びそれを用いるインドキシル硫酸の検出方法
EP0479929A1 (fr)	1992-04-15	Analyse de vitamine b12.
EP0433452A1 (fr)	1991-06-26	Anticorps monoclonal, et procede d'analyse, kit de reactif, procede de recherche et medicament utilisant ledit anticorps
JP4663831B2 (ja)	2011-04-06	モノクローナル抗体、細胞株及びｎ１，ｎ１２−ジアセチルスペルミンの測定法
US5298397A (en)	1994-03-29	Method of assaying d-vanillylmandelic acid
JP2896931B2 (ja)	1999-05-31	モノクローナル抗体、それを用いた測定法、試薬キット、検索法及び薬剤ミサイル
US5650284A (en)	1997-07-22	Enhancing the sensitivity of immunoassay procedures by use of antibodies directed to the product of a reaction between probe labels and assay substrates
JPH06507314A (ja)	1994-08-25	ヒトチミジル酸シンターゼに特異的なモノクローナル抗体
JPWO1990010708A1 (ja)	1991-02-07	モノクローナル抗体、それを用いた測定法、試薬キット、検索法及び薬剤ミサイル
JPH0379994B2 (fr)	1991-12-20
JPH11318448A (ja)	1999-11-24	抗原、抗体およびそれを用いる免疫学的測定方法
AU2002346529B2 (en)	2009-02-12	Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample
RU2049816C1 (ru)	1995-12-10	Штамм гибридных культивируемых клеток мыши mus musculus l., используемый для получения моноклональных антител к тироксину
JP2004091454A (ja)	2004-03-25	抗体及びその製造方法並びに抗体を用いた抗原の定量方法

Legal Events

Date	Code	Title	Description
1992-09-08	FZDE	Dead